Thermo Fisher Scientific Inc (NYSE: TMO) announced on Wednesday that it has unveiled its next-generation Gibco CHOvantage GS Cell Line Development (CLD) Kit, an integrated platform designed to accelerate biologics development while supporting regulatory compliance and scalable manufacturing.

The platform enables researchers to generate high-performing CHO cell lines, achieving protein titers of ≥7 g/L in fed-batch cultures, establish stable pools in as little as four weeks, and select stable clones within 14 weeks. The system aims to streamline progression from early development to commercial-scale production, supporting both complex biologics and biosimilars amid growing global demand.

A key feature of the CHOvantage GS CLD Kit is its royalty-free, clinical-stage licensing, allowing developers to avoid common fees during clinical development and providing cost predictability and commercial flexibility for seamless scale-up.

According to the company, the platform addresses the need for faster, reliable and consistent biologics manufacturing, helping companies reduce timelines and maintain quality across protein therapeutics for cancer, autoimmune, rare diseases and other indications.

Thermo Fisher Scientific is a global leader in serving science, delivering technologies and services across life sciences research, diagnostics, and pharmaceutical manufacturing through brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.